Drug Trial Radar · NCT04767802
PTG-300 in Patients With Polycythemia Vera and Elevated Hematocrit
Last checked: Nov 20, 2026Latest source record: Mar 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20
Actual
Start
Feb 2, 2021
Primary completion
Mar 15, 2023
Study completion Mar 15, 2023
Sponsor
- Lead sponsor
- Protagonist Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 23, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open label, single arm trial of PTG-300 in subjects with PV who are newly diagnosed or for whom current therapy is not sufficient to control their hematocrit and have hematocrit \>48% prior to dosing. The PTG-300 dose and schedule may be adjusted every 2 to 4 weeks to maintain hematocrit \<45% with a target of \<43%. Subjects may receive PTG-300 treatment for up to 52 weeks.
Conditions
- Polycythemia Vera
Interventions
PTG-300Drug
Hepcidin mimetic
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate PTG-300's efficacy in subjects with PV and baseline elevated hematocrit.Time frame: Estimate the proportion of subject with a hematocrit less than 45% at Week 16
Locations
8 sites in 2 countries. Site status is shown where the registry gives one.
Hospital Sultanah Aminah
Johor Bahru, Johor, Malaysia
Hospital Raja Perempuan Zainab
Kota Bharu, Kelantan, Malaysia
Hospital Raja Permaisuki Bainun
Ipoh, Perak, Malaysia
Hospital Umum Sarawak
Kuching, Sarawak, Malaysia
Hospital Ampang
Ampang, Selangor, Malaysia
Gachon University Medical Center
Incheon, South Korea
Seoul National University Hospital
Seoul, South Korea
Seoul St. Mary's Catholic University Hospital
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.